Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, January 22, 2010

abstract: Association of Skeletal Muscle Wasting With Treatment With Sorafenib

Note: this study is not specific to ovarian cancer but may be of interest for those deciding on Sorafenib:
"Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue, and physical disability."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.